Why Is bioAffinity Technologies (BIAF) Stock Up +48.12% Today?
Key Takeaways
- Shares surged roughly 48.12% intraday on Thursday, extending a multi-day rally for the micro-cap diagnostics company.
- The primary catalyst was the company's plan to expand its CyPath® Lung test into post-treatment surveillance of lung cancer survivors.
- Elevated speculative volume and a small float are amplifying the price move, a hallmark of heavily traded micro-cap biotechs.
- The company's announcement of participation in the H.C. Wainwright Global Investment Conference added to investor attention.
- Traders are watching for any follow-on clinical validation, financing activity, or profit-taking after the rapid run-up.
Opening Summary
bioAffinity Technologies, Inc. (BIAF), a San Antonio, Texas-based biotechnology company focused on noninvasive diagnostics for early-stage lung cancer detection, saw its stock surge sharply on Thursday. Shares climbed to about $18.93, up from the prior session's close of $12.78, a gain of approximately 48.12%. The advance extended a powerful rally that began earlier in the week after the company announced it was advancing the application of its flagship CyPath® Lung test into the surveillance of lung cancer patients who have completed curative-intent treatment.
Catalyst: CyPath® Lung Expansion Into Cancer Surveillance
The dominant driver behind the stock's surge is BIAF's move to broaden the commercial use of CyPath® Lung, a noninvasive diagnostic that uses flow cytometry and proprietary artificial intelligence to identify malignant cell populations in a patient's sputum. The company said it is advancing the test for ongoing monitoring of lung cancer survivors, positioning it as a complement to CT imaging in detecting recurrence or new cancers.
The addressable market is substantial. According to the American Cancer Society, more than 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025, while the National Cancer Institute estimates another 230,000 new diagnoses in 2026. Published studies report recurrence rates of roughly 20% to 55% for non-small cell lung cancer, underscoring the clinical need for better surveillance tools. CyPath® Lung has demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in its detection setting, though those figures have not yet been separately validated for post-treatment surveillance.
Secondary Driver: Investor Conference and Corporate Momentum
Adding to the positive sentiment, the company announced that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in mid-September. The presentation is expected to highlight commercial adoption and momentum for CyPath® Lung, as well as additional diagnostics and therapeutics under development. For a micro-cap name with limited analyst coverage, such events can focus institutional attention and fuel additional buying interest.
Market Context and Trading Activity
The price move is being amplified by extreme trading volume relative to BIAF's small float. Daily volume has reached into the tens of millions of shares at points this week — an enormous figure for a company whose total market capitalization was roughly $7 million to $8 million — indicating intense speculative and momentum-driven activity rather than purely fundamental repositioning. The stock also recently underwent a 1-for-15 reverse stock split effective August 24, 2026, which reduced the share count and can magnify percentage swings in thinly traded names.
The move appears largely company-specific rather than driven by broad market or sector forces. While the biotechnology and diagnostics space has seen periodic enthusiasm for AI-enabled health screening, BIAF's outsized gains this week reflect the CyPath® Lung catalyst and the mechanics of a low-float stock under heavy buying pressure. Traders should note that such parabolic moves can reverse quickly once momentum fades or profit-taking begins.
What Comes Next for BIAF
Looking ahead, investors will be watching for the company's H.C. Wainwright presentation in mid-September, any additional commercial or distribution updates for CyPath® Lung, and progress toward validating the test for post-treatment surveillance. BIAF remains a development-stage company with a history of losses and a continuing need for capital, so financing decisions and cash runway are important considerations. Risks include the lack of separately validated clinical data for the surveillance application, competitive pressure in the lung diagnostics market, and the inherent volatility of a micro-cap stock that has more than tripled in a matter of days.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Investors interested in data-driven approaches to volatile names like BIAF can explore the Trending AI Robots section to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BIAF in downward trend: 10-day moving average moved below 50-day moving average on September 03, 2026
The 10-day moving average for BIAF crossed bearishly below the 50-day moving average on September 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIAF as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIAF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BIAF just turned positive on September 23, 2026. Looking at past instances where BIAF's MACD turned positive, the stock continued to rise in 33 of 34 cases over the following month. The odds of a continued upward trend are 90%.
Following a +76.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIAF advanced for three days, in 119 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.181) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (0.229) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. BIAF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement